Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1-2 study
Last Updated: Monday, March 24, 2025
Talquetamab, a GPRC5D-targeted bispecific antibody, has shown high overall response rates in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM). The MonumenTAL-1 study demonstrated promising activity even in patients who had received previous T-cell redirection therapy.
Advertisement
News & Literature Highlights